Evan David Seigerman
Stock Analyst at BMO Capital
(2.90)
# 1,731
Out of 4,996 analysts
48
Total ratings
43.18%
Success rate
1.12%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Evan David Seigerman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABBV AbbVie | Maintains: Outperform | $215 → $240 | $220.61 | +8.79% | 8 | Sep 12, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $600 → $640 | $563.90 | +13.50% | 8 | Aug 4, 2025 | |
| REPL Replimune Group | Downgrades: Underperform | $27 → $2 | $4.13 | -51.57% | 4 | Jul 23, 2025 | |
| NGNE Neurogene | Maintains: Outperform | $22 → $26 | $17.82 | +45.90% | 2 | Jun 12, 2025 | |
| MRUS Merus | Maintains: Outperform | $96 → $110 | $68.89 | +59.67% | 1 | May 23, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Outperform | $24 → $28 | $21.05 | +33.02% | 2 | May 19, 2025 | |
| ARVN Arvinas | Maintains: Outperform | $20 → $10 | $8.27 | +20.92% | 1 | May 5, 2025 | |
| NVO Novo Nordisk | Downgrades: Market Perform | $105 → $64 | $55.61 | +15.09% | 6 | Apr 17, 2025 | |
| MRK Merck & Co. | Maintains: Market Perform | $105 → $96 | $78.56 | +22.20% | 4 | Feb 5, 2025 | |
| AMGN Amgen | Maintains: Outperform | $362 → $346 | $272.98 | +26.75% | 4 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $83 → $100 | $25.00 | +300.00% | 2 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $33 → $36 | $23.76 | +51.52% | 4 | May 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $3 | $5.54 | -45.85% | 1 | May 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $369 → $396 | $724.54 | -45.34% | 1 | Sep 6, 2022 |
AbbVie
Sep 12, 2025
Maintains: Outperform
Price Target: $215 → $240
Current: $220.61
Upside: +8.79%
Regeneron Pharmaceuticals
Aug 4, 2025
Maintains: Outperform
Price Target: $600 → $640
Current: $563.90
Upside: +13.50%
Replimune Group
Jul 23, 2025
Downgrades: Underperform
Price Target: $27 → $2
Current: $4.13
Upside: -51.57%
Neurogene
Jun 12, 2025
Maintains: Outperform
Price Target: $22 → $26
Current: $17.82
Upside: +45.90%
Merus
May 23, 2025
Maintains: Outperform
Price Target: $96 → $110
Current: $68.89
Upside: +59.67%
ACADIA Pharmaceuticals
May 19, 2025
Maintains: Outperform
Price Target: $24 → $28
Current: $21.05
Upside: +33.02%
Arvinas
May 5, 2025
Maintains: Outperform
Price Target: $20 → $10
Current: $8.27
Upside: +20.92%
Novo Nordisk
Apr 17, 2025
Downgrades: Market Perform
Price Target: $105 → $64
Current: $55.61
Upside: +15.09%
Merck & Co.
Feb 5, 2025
Maintains: Market Perform
Price Target: $105 → $96
Current: $78.56
Upside: +22.20%
Amgen
Jan 29, 2025
Maintains: Outperform
Price Target: $362 → $346
Current: $272.98
Upside: +26.75%
Jun 7, 2024
Maintains: Outperform
Price Target: $83 → $100
Current: $25.00
Upside: +300.00%
May 2, 2024
Reiterates: Outperform
Price Target: $33 → $36
Current: $23.76
Upside: +51.52%
May 15, 2023
Maintains: Outperform
Price Target: $9 → $3
Current: $5.54
Upside: -45.85%
Sep 6, 2022
Maintains: Outperform
Price Target: $369 → $396
Current: $724.54
Upside: -45.34%